Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK

OBJECTIVE: To determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active ankylosing spondylitis (AS) who have not responded adequately to previous treatment with conventional care (CC; biologic-naïve population) or previous biologic the...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Pharmacoeconomics
Main Authors: Emery, Paul, Van Keep, Marjolijn, Beard, Steve, Graham, Chris, Miles, LaStella, Jugl, Steffen Marc, Gunda, Praveen, Halliday, Anna, Marzo-Ortega, Helena
Format: Artigo
Sprog:Inglês
Udgivet: Springer International Publishing 2018
Fag:
Original Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021464/
https://ncbi.nlm.nih.gov/pubmed/29797186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-018-0675-9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker